Lipid-Based Pharma Excipients Market - Global Outlook & Forecast 2025-2030

The global lipid-based pharma excipients market is expected to grow at a CAGR of 5.63% from 2024 to 2030.

MARKET TRENDS & DRIVERS

Shift Toward Natural and Biodegradable Lipid Excipients

The pharmaceutical industry is undergoing a paradigm shift, accounting for increased attention to sustainability and biocompatibility. In this context, the global lipid-based pharma excipients market is embracing a transition toward natural and biodegradable lipid excipients. This trend is opening doors to innovative growth avenues by catering to the consumer demand for greener alternatives, the regulatory pressure for environment-friendly products, and the advancements in pharmaceutical formulations. Several key factors are contributing to the growing interest in natural and biodegradable lipid excipients in the pharmaceutical industry. For instance, consumers are increasingly favoring sustainable and environmentally conscious pharmaceutical products. The demand for clean-label medications, driven by the same consumer trends influencing food and cosmetics, is accelerating the adoption of natural excipients derived from plant sources. Moreover, governments and regulatory bodies worldwide are pushing for the adoption of sustainable and biodegradable materials in the pharmaceutical sector. Compliance with environmental regulations, such as the European Green Deal and similar initiatives, is incentivizing manufacturers to transition to biodegradable excipients.

Advancements in Lipid Nanoparticles and Drug Delivery Systems

The pharmaceutical industry has witnessed remarkable advancements in drug delivery systems over the past decade, with lipid nanoparticles (LNPs) emerging as one of the most promising technologies. Lipid-based formulations, particularly LNPs, have gained significant attention due to their ability to enhance the stability, bioavailability, and targeted delivery of therapeutics. This technological evolution is creating substantial opportunities for the global lipid-based pharma excipients market, driven by the growing demand for innovative drug delivery solutions. The advancements in lipid nanoparticles are driving the demand for high-quality lipid-based excipients. These excipients, including phospholipids, triglycerides, and cholesterol, are integral to the stability and functionality of LNP formulations.

Advancements in Lipid Processing Technologies

The pharmaceutical industry is undergoing rapid transformation, with an increasing emphasis on advanced drug delivery systems. Lipid-based excipients have become essential components in the formulation of poorly water-soluble drugs due to their ability to improve bioavailability and stability. The advancements in lipid processing technologies, such as spray drying, melt extrusion, and co-crystallization, have revolutionized the production and application of lipid-based excipients. These new technologies address key challenges in drug formulation, driving the lipid-based pharma excipients market growth and enabling pharmaceutical manufacturers to meet the growing demand for sophisticated drug delivery solutions. Moreover, the production and optimization of lipid-based excipients require advanced processing techniques to ensure consistent quality, stability, and performance. Traditional lipid processing methods often face limitations such as poor extensibility, low encapsulation efficiency, and difficulty in controlling particle size. The recent advancements in lipid processing technology have overcome these limitations, paving the way for the development of advanced excipients and drug formulations.

Rising Consumer Demand for Oral and Topical Formulations

The global pharmaceutical industry is witnessing a significant shift toward patient-friendly drug delivery systems, with oral and topical dosage forms gaining popularity among consumers. This growing demand is driving the expansion of the lipid-based pharma excipients market. As pharmaceutical companies increasingly focus on patient-centric drug development, the use of lipid excipients in oral and topical drug delivery is gaining importance. Moreover, oral and topical drug delivery systems have gained immense popularity due to their ease of administration, better patient compliance, and non-invasive nature.

Growth of Biopharmaceuticals and mRNA-Based Therapies

The rapid advancements in biopharmaceuticals and mRNA-based therapies have fueled the demand for specialized drug delivery systems, leading to significant growth in the lipid-based pharma excipients market. Lipid-based excipients, including phospholipids, glycerides, and sterols, play a critical role in drug solubility, stability, and bioavailability, making them essential components in modern drug formulation. Moreover, biopharmaceuticals, including monoclonal antibodies, gene therapies, and cell-based treatments, have emerged as the dominant force in the pharmaceutical industry. With biologics accounting for over 40% of new drug approvals globally, the demand for lipid-based excipients has surged due to their ability to enhance drug absorption and stability. The growing prevalence of chronic diseases such as cancer, autoimmune disorders, and rare genetic conditions has further accelerated biopharmaceutical development, directly benefiting lipid-excipient manufacturers.

SEGMENTATION INSIGHTS

INSIGHTS BY PRODUCT TYPE

The global lipid-based pharma excipients market by product type is segmented into fats, phospholipids, oils, waxes, and others. Fats are a vital component of the market, holding the most significant segment share and playing a significant role in enhancing drug solubility, stability, and controlled release. Their applications span oral, injectable, and topical formulations, contributing to improved bioavailability and patient compliance. With the rising demand for lipid-based drug delivery systems, biologics, and personalized medicine, the market for fat-based pharma excipients is poised for substantial growth in the future. Moreover, phospholipids are a vital category of the lipid-based pharma excipients market, offering unique advantages in drug solubility, stability, and targeted delivery. Their ability to form self-assembled nanostructures makes them essential for modern drug formulation strategies, including liposomes, emulsions, and lipid nanoparticles. As research progresses, phospholipids will continue to play a pivotal role in developing innovative and efficient drug delivery systems.

Segmentation by Product Type

  • Fats
  • Phospholipids
  • Oils
  • Waxes
  • Others
INSIGHTS BY FUNCTIONALITY

The global lipid-based pharma excipients market by functionality is segmented into solubilizers & wetting agents, emulsifiers & surfactants, structuring agents & lubricants, emollients, penetration enhancers and solvents, and others. The solubilizers & wetting agents segment holds the most significant market share. In pharmaceutical formulations, excipients play a critical role in enhancing drug performance, stability, and bioavailability. Among these, lipid-based excipients have gained prominence due to their ability to improve the solubility and dispersion of poorly water-soluble drugs. Two of their key functionalities are their use as solubilizers and wetting agents, which are crucial in optimizing drug delivery and therapeutic efficacy. Also, many active pharmaceutical ingredients (APIs) suffer from poor aqueous solubility, leading to low bioavailability when administered orally. Lipid-based excipients act as solubilizers by incorporating these hydrophobic drugs into lipid structures, thereby enhancing their dissolution and absorption in the gastrointestinal (GI) tract.

Segmentation by Functionality
  • Solubilizers & Wetting Agents
  • Emulsifiers & Surfactants
  • Structuring Agents & Lubricants
  • Emollients, Penetration Enhancers, & Solvents
  • Others
INSIGHTS BY FORMULATION

The global lipid-based pharma excipients market by formulation is segmented into enteral, injectables, and topical. The enteral segment holds the most prominent share of the global market in 2024. Lipid-based pharma excipients play a crucial role in enteral drug formulations, which include oral and rectal dosage forms such as solid orals, liquid orals, suppositories, and pessaries. Lipid-based excipients are used in various enteral formulations to optimize drug solubility, absorption, and therapeutic efficacy. These excipients include fatty acids, triglycerides, phospholipids, emulsifiers, and waxes, which serve different functional roles depending on the type of formulation.

Segmentation by Formulation
  • Enteral
  • Injectables
  • Topical
INSIGHTS BY END-USER

The pharma & biotech companies by end-user hold the most significant share of the global lipid-based pharma excipients market. In pharmaceutical productions, lipid excipients have become popular and are now largely used to enhance the solubility of active ingredients. Lipid-based formulations allow increasing bioavailability of lipophilic active ingredients that would otherwise be poorly water-soluble. These factors are essential for oral formulations in pharmaceutical production. Pharma & biotech companies drive the highest demand for lipid-based excipients due to increasing production capacity, rising competition for market penetration, goals to deliver the highest-quality products, and stay competent with achieving the highest volume and revenue across the industry. Furthermore, CMOs are the second largest revenue contributor in the global lipid-based pharma excipients market. During the forecast period 2024-2030, the CMOs segment is expected to grow with the highest CAGR of 6.27%. CMOs have become the cornerstone of pharmaceutical manufacturing. Small & mid-sized, and large pharma companies are rapidly turning towards CMOs as they offer cost-effective contract manufacturing services.

Segmentation by End-User
  • Pharma & Biotech Companies
  • Contract Manufacturing Organizations (CMOs)
  • Contract Research Organizations (CROs) & Contract Development and Manufacturing Organizations (CDMOs)
  • Academic & Research Institutes
GEOGRAPHICAL ANALYSIS

The global lipid-based pharma excipients market is expanding rapidly, driven by the growing demand for lipid-based drug delivery systems, the increased adoption of lipid nanoparticles in vaccines, and advancements in drug solubility enhancement technologies. North America, particularly the U.S. and Canada, holds a dominant position in the lipid-based pharma excipients market. The region benefits from a well-established pharmaceutical industry, strong R&D capabilities, and a high level of regulatory compliance. Furthermore, the U.S. is home to major pharmaceutical giants, such as Pfizer, Merck, and Moderna, which extensively use lipid-based excipients in drug formulations, including lipid nanoparticles for mRNA vaccines.

Europe is another major player in the global lipid-based pharma excipients market, with key countries including Germany, Switzerland, Ireland, Belgium, Italy, and the UK. The region is known for its focus on high-quality and sustainably sourced lipid excipients as well as strong pharmaceutical manufacturing capabilities. Furthermore, APAC is experiencing the fastest growth in the lipid-based pharma excipients market, with key contributors including China, Japan, India, South Korea, and Australia. This growth is fueled by rising pharmaceutical manufacturing, increasing investments in drug delivery technologies, and cost-effective production.

Latin America is an emerging lipid-based pharma excipients market, with key countries including Brazil, Mexico, Argentina, and Colombia. The region is witnessing increased pharmaceutical production, particularly in generic drugs and contract manufacturing. The region is home to a rapidly expanding generic drug market, and lipid-based excipients play a crucial role in the formulation of generic and innovative drugs, especially those requiring improved bioavailability. Furthermore, the Middle East & Africa region represents a nascent but growing lipid-based pharma excipients market. The key countries driving demand include Turkey, Saudi Arabia, the UAE, and South Africa. The market is supported by increasing investments in pharmaceutical production and healthcare infrastructure. Also, the region's expanding population and improving healthcare systems are increasing the need for advanced drug formulations.

Segmentation by Geography
  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • Switzerland
  • Ireland
  • Belgium
  • Italy
  • France
  • Netherlands
  • The U.K.
  • Spain
  • APAC
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Middle East & Africa
  • Turkey
  • South Africa
  • Saudi Arabia
  • UAE
COMPETITIVE LANDSCAPE

The global lipid-based pharmaceutical excipients market has witnessed considerable growth in recent years, driven by increasing demand for novel drug delivery systems and the growing need for high-quality excipients to improve drug formulation. Lipid-based excipients, such as solid lipid nanoparticles, liposomes, and lipid emulsions, play a crucial role in enhancing the bioavailability, stability, and targeted delivery of poorly soluble drugs. As the demand for such excipients continues to rise, the competition in the lipid-based pharma excipients market has intensified, with several global players striving to gain a larger market share by offering innovative solutions and establishing strategic partnerships.

Innovation is at the forefront of the competitive strategies of many players in the lipid-based excipients market. Companies in the lipid-based pharma excipients market are focusing on developing new lipid formulations, enhancing existing products, and exploring novel drug delivery systems. For example, advancements in lipid nanoparticles and liposomes for drug encapsulation are driving growth in the lipid-based pharma excipients market. Significant R&D investments are critical to staying ahead in the competitive landscape. Players like BASF and Lonza are constantly upgrading their product offerings to cater to emerging market needs. Furthermore, collaboration with other pharmaceutical and biotechnology firms is another key strategy for growth. Companies in the lipid-based pharma excipients market often form partnerships with drug manufacturers to develop specialized formulations for specific therapeutic areas. Additionally, acquisitions play a vital role in strengthening product portfolios and expanding market reach. Evonik Industries, for example, has expanded its presence through strategic acquisitions in the biopharmaceutical and excipient sectors.

Key Vendors
  • ABF Ingredients – ABITEC
  • BASF
  • Croda International
  • Gattefosé
  • IOI Oleo GMbH
  • Merck KGaA
Other Prominent Vendors
  • AAK
  • Alsiano
  • Biopharma PEG Scientific
  • CD Formulation
  • CLARIANT
  • Colorcon
  • CordenPharma
  • CREMER OLEO
  • Evonik
  • Kao Corporation
  • Lipoid
  • NOF CORPORATION
  • Pothe Hille & Co
  • The East Africa Wax Company
  • VAV Life Sciences (VAV)
  • WAXOILS
KEY QUESTIONS ANSWERED:

1. How big is the global lipid-based pharma excipients market?

2. What is the growth rate of the global lipid-based pharma excipients market?

3. Which region dominates the global lipid-based pharma excipients market share?

4. Who are the key players in the global lipid-based pharma excipients market?

5. What are the significant trends in the lipid-based pharma excipients industry?


1. SCOPE & COVERAGE
1.1. MARKET DEFINITION
1.1.1. INCLUSIONS
1.1.2. EXCLUSIONS
1.1.3. MARKET ESTIMATION CAVEATS
1.2. MARKET SEGMENTATION COVERAGE & DEFINITIONS
1.2.1. PRODUCT TYPE
1.2.2. FUNCTIONALITY
1.2.3. FORMULATION
1.2.4. END-USER
1.3. MARKET DERIVATION
BASE YEAR
2. PREMIUM INSIGHTS
2.1. OVERVIEW
2.2. OPPORTUNITY POCKETS
3. MARKET AT A GLANCE
4. INTRODUCTION
4.1. OVERVIEW
4.1.1. KEY CUSTOMER DEMANDS FROM DRUG PRODUCERS
4.1.2. VALUE CHAIN DEVELOPMENTS
5. MARKET OPPORTUNITIES & TRENDS
5.1. GROWING SIGNIFICANCE OF CO-PROCESSED EXCIPIENTS
5.2. EXPANDING USE OF LIPID EXCIPIENTS IN COMBINATION THERAPIES
5.3. GROWING DEVELOPMENT OF LONG-ACTING INJECTABLE (LAI) DEPOT FORMULATIONS
5.4. GROWING EMPHASIS ON DEVELOPMENT OF MULTIFUNCTIONAL LIPID-EXCIPIENTS
5.5. SHIFT TOWARD NATURAL AND BIODEGRADABLE LIPID EXCIPIENTS
5.6. ADVANCEMENTS IN LIPID NANOPARTICLES AND DRUG DELIVERY SYSTEMS
6. MARKET GROWTH ENABLERS
6.1. ADVANCEMENTS IN LIPID PROCESSING TECHNOLOGIES
6.2. RISING CONSUMER DEMAND FOR ORAL AND TOPICAL FORMULATIONS
6.3. GROWTH OF BIOPHARMACEUTICALS AND MRNA-BASED THERAPIES
6.4. FAVORABLE GOVERNEMENT INITIATIVES
6.5. GROWTH IN SELF-EMULSIFYING DRUG DELIVERY SYSTEM (SEDDS)
6.6. GROWING FOCUS ON BIOLOGICS SPURRING INCREASED INVESTMENTS IN BIOLOGIC EXCIPIENTS
7. MARKET RESTRAINTS
7.1. SUPPLY CHAIN & RAW MATERIAL SOURCING ISSUES
7.2. AVAILABILITY OF ALTERNATIVE PHARMA EXCIPIENTS
7.3. COMPLEX MANUFACTURING AND PROCESSING OF LIPID EXCIPIENTS
7.4. REGULATORY AND QUALITY CONCERNS
8. MARKET LANDSCAPE
8.1. MARKET OVERVIEW
8.2. MARKET SIZE & FORECAST
8.3. FIVE FORCES ANALYSIS
8.3.1. THREAT OF NEW ENTRANTS
8.3.2. BARGAINING POWER OF SUPPLIERS
8.3.3. BARGAINING POWER OF BUYERS
8.3.4. THREAT OF SUBSTITUTES
8.3.5. COMPETITIVE RIVALRY
9. PRODUCT TYPE
9.1. MARKET SNAPSHOT & GROWTH ENGINE
9.2. MARKET OVERVIEW
9.3. FATS
9.3.1. MARKET OVERVIEW
9.3.2. MARKET SIZE & FORECAST
9.3.3. MARKET BY GEOGRAPHY
9.4. PHOSPHOLIPIDS
9.4.1. MARKET OVERVIEW
9.4.2. MARKET SIZE & FORECAST
9.4.3. MARKET BY GEOGRAPHY
9.5. OILS
9.5.1. MARKET OVERVIEW
9.5.2. MARKET SIZE & FORECAST
9.5.3. MARKET BY GEOGRAPHY
9.6. WAXES
9.6.1. MARKET OVERVIEW
9.6.2. MARKET SIZE & FORECAST
9.6.3. MARKET BY GEOGRAPHY
9.7. OTHERS
9.7.1. MARKET OVERVIEW
9.7.2. MARKET SIZE & FORECAST
9.7.3. MARKET BY GEOGRAPHY
10. FUNCTIONALITY
10.1. MARKET SNAPSHOT & GROWTH ENGINE
10.2. MARKET OVERVIEW
10.3. SOLUBILIZERS & WETTING AGENTS
10.3.1. MARKET OVERVIEW
10.3.2. MARKET SIZE & FORECAST
10.3.3. MARKET BY GEOGRAPHY
10.4. EMULSIFIER & SURFACTANT
10.4.1. MARKET OVERVIEW
10.4.2. MARKET SIZE & FORECAST
10.4.3. MARKET BY GEOGRAPHY
10.5. STRUCTURING AGENTS & LUBRICANTS
10.5.1. MARKET OVERVIEW
10.5.2. MARKET SIZE & FORECAST
10.5.3. MARKET BY GEOGRAPHY
10.6. EMOLLIENTS, PENETRATION ENHANCERS, & SOLVENTS
10.6.1. MARKET OVERVIEW
10.6.2. MARKET SIZE & FORECAST
10.6.3. MARKET BY GEOGRAPHY
10.7. OTHERS
10.7.1. MARKET OVERVIEW
10.7.2. MARKET SIZE & FORECAST
10.7.3. MARKET BY GEOGRAPHY
11. FORMULATION
11.1. MARKET SNAPSHOT & GROWTH ENGINE
11.2. MARKET OVERVIEW
11.3. ENTERAL
11.3.1. MARKET OVERVIEW
11.3.2. MARKET SIZE & FORECAST
11.3.3. MARKET BY GEOGRAPHY
11.4. INJECTABLES
11.4.1. MARKET OVERVIEW
11.4.2. MARKET SIZE & FORECAST
11.4.3. MARKET BY GEOGRAPHY
11.5. TOPICAL
11.5.1. MARKET OVERVIEW
11.5.2. MARKET SIZE & FORECAST
11.5.3. MARKET BY GEOGRAPHY
12. END-USERS
12.1. MARKET SNAPSHOT & GROWTH ENGINE
12.2. MARKET OVERVIEW
12.3. PHARMA & BIOTECH COMPANIES
12.3.1. MARKET OVERVIEW
12.3.2. MARKET SIZE & FORECAST
12.3.3. MARKET BY GEOGRAPHY
12.4. CONTRACT MANUFACTURING ORGANIZATIONS (CMOS)
12.4.1. MARKET OVERVIEW
12.4.2. MARKET SIZE & FORECAST
12.4.3. MARKET BY GEOGRAPHY
12.5. CONTRACT RESEARCH ORGANIZATIONS & CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CROS & CDMOS)
12.5.1. MARKET OVERVIEW
12.5.2. MARKET SIZE & FORECAST
12.5.3. MARKET BY GEOGRAPHY
12.6. ACADEMIC & RESEARCH INSTITUTE
12.6.1. MARKET OVERVIEW
12.6.2. MARKET SIZE & FORECAST
12.6.3. MARKET BY GEOGRAPHY
13. GEOGRAPHY
13.1. MARKET SNAPSHOT & GROWTH ENGINE
13.2. GEOGRAPHIC OVERVIEW
14. NORTH AMERICA
14.1. MARKET OVERVIEW
14.2. MARKET SIZE & FORECAST
14.2.1. PRODUCT TYPE
14.2.2. FUNCTIONALITY
14.2.3. FORMULATION
14.2.4. END-USER
14.3. KEY COUNTRIES
14.3.1. US: MARKET SIZE & FORECAST
14.3.2. CANADA: MARKET SIZE & FORECAST
15. EUROPE
15.1. MARKET OVERVIEW
15.2. MARKET SIZE & FORECAST
15.2.1. PRODUCT TYPE
15.2.2. FUNCTIONALITY
15.2.3. FORMULATION
15.2.4. END-USER
15.3. KEY COUNTRIES
15.3.1. GERMANY: MARKET SIZE & FORECAST
15.3.2. SWITZERLAND: MARKET SIZE & FORECAST
15.3.3. IRELAND: MARKET SIZE & FORECAST
15.3.4. BELGIUM: MARKET SIZE & FORECAST
15.3.5. ITALY: MARKET SIZE & FORECAST
15.3.6. FRANCE: MARKET SIZE & FORECAST
15.3.7. NETHERLANDS: MARKET SIZE & FORECAST
15.3.8. UK: MARKET SIZE & FORECAST
15.3.9. SPAIN: MARKET SIZE & FORECAST
16. APAC
16.1. MARKET OVERVIEW
16.2. MARKET SIZE & FORECAST
16.2.1. PRODUCT TYPE
16.2.2. FUNCTIONALITY
16.2.3. FORMULATION
16.2.4. END-USER
16.3. KEY COUNTRIES
16.3.1. CHINA: MARKET SIZE & FORECAST
16.3.2. JAPAN: MARKET SIZE & FORECAST
16.3.3. INDIA: MARKET SIZE & FORECAST
16.3.4. SOUTH KOREA: MARKET SIZE & FORECAST
16.3.5. AUSTRALIA: MARKET SIZE & FORECAST
17. LATIN AMERICA
17.1. MARKET OVERVIEW
17.2. MARKET SIZE & FORECAST
17.2.1. PRODUCT TYPE
17.2.2. FUNCTIONALITY
17.2.3. FORMULATION
17.2.4. END-USER
17.3. KEY COUNTRIES
17.3.1. BRAZIL: MARKET SIZE & FORECAST
17.3.2. MEXICO: MARKET SIZE & FORECAST
17.3.3. ARGENTINA: MARKET SIZE & FORECAST
17.3.4. COLOMBIA: MARKET SIZE & FORECAST
18. MIDDLE EAST & AFRICA
18.1. MARKET OVERVIEW
18.2. MARKET SIZE & FORECAST
18.2.1. PRODUCT TYPE
18.2.2. FUNCTIONALITY
18.2.3. FORMULATION
18.2.4. END-USER
18.3. KEY COUNTRIES
18.3.1. TURKEY: MARKET SIZE & FORECAST
18.3.2. SOUTH AFRICA: MARKET SIZE & FORECAST
18.3.3. SAUDI ARABIA: MARKET SIZE & FORECAST
18.3.4. UAE: MARKET SIZE & FORECAST
19. COMPETITIVE LANDSCAPE
19.1. COMPETITION OVERVIEW
19.2. MARKET SHARE ANALYSIS
19.2.1. BASF
19.2.2. ABITEC
19.2.3. MERCK KGAA
19.2.4. GATTEFOSSÉ
19.2.5. CRODA INTERNATIONAL
19.2.6. IOI OLEO GMBH
20. KEY COMPANY PROFILES
20.1. ABF INGREDIENTS - ABITEC
20.1.1. BUSINESS OVERVIEW
20.1.2. PRODUCT OFFERINGS
20.1.3. KEY STRATEGIES
20.1.4. KEY STRENGTHS
20.1.5. KEY OPPORTUNITIES
20.2. BASF
20.2.1. BUSINESS OVERVIEW
20.2.2. PRODUCT OFFERINGS
20.2.3. KEY STRATEGIES
20.2.4. KEY STRENGTHS
20.2.5. KEY OPPORTUNITIES
20.3. CRODA INTERNATIONAL
20.3.1. BUSINESS OVERVIEW
20.3.2. PRODUCT OFFERINGS
20.3.3. KEY STRATEGIES
20.3.4. KEY STRENGTHS
20.3.5. KEY OPPORTUNITIES
20.4. GATTEFOSÉ
20.4.1. BUSINESS OVERVIEW
20.4.2. PRODUCT OFFERINGS
20.4.3. KEY STRATEGIES
20.4.4. KEY STRENGTHS
20.4.5. KEY OPPORTUNITIES
20.5. IOI OLEO GMBH
20.5.1. BUSINESS OVERVIEW
20.5.2. PRODUCT OFFERINGS
20.5.3. KEY STRATEGIES
20.5.4. KEY STRENGTHS
20.5.5. KEY OPPORTUNITIES
20.6. MERCK KGAA
20.6.1. BUSINESS OVERVIEW
20.6.2. PRODUCT OFFERINGS
20.6.3. KEY STRATEGIES
20.6.4. KEY STRENGTHS
20.6.5. KEY OPPORTUNITIES
21. OTHER PROMINENT VENDORS
21.1. AAK
21.1.1. BUSINESS OVERVIEW
21.1.2. PRODUCT OFFERINGS
21.2. ALSIANO
21.2.1. BUSINESS OVERVIEW
21.2.2. PRODUCT OFFERINGS
21.3. BIOPHARMA PEG SCIENTIFIC
21.3.1. BUSINESS OVERVIEW
21.3.2. PRODUCT OFFERINGS
21.4. CD FORMULATION
21.4.1. BUSINESS OVERVIEW
21.4.2. PRODUCT OFFERINGS
21.5. CLARIANT
21.5.1. BUSINESS OVERVIEW
21.5.2. PRODUCT OFFERINGS
21.6. COLORCON
21.6.1. BUSINESS OVERVIEW
21.6.2. PRODUCT OFFERINGS
21.7. CORDENPHARMA
21.7.1. BUSINESS OVERVIEW
21.7.2. PRODUCT OFFERINGS
21.8. CREMER OLEO
21.8.1. BUSINESS OVERVIEW
21.8.2. PRODUCT OFFERINGS
21.9. EVONIK
21.9.1. BUSINESS OVERVIEW
21.9.2. PRODUCT OFFERINGS
21.10. KAO CORPORATION
21.10.1. BUSINESS OVERVIEW
21.10.2. PRODUCT OFFERINGS
21.11. LIPOID
21.11.1. BUSINESS OVERVIEW
21.11.2. PRODUCT OFFERINGS
21.12. NOF CORPORATION
21.12.1. BUSINESS OVERVIEW
21.12.2. PRODUCT OFFERINGS
21.13. POTH HILLE & CO
21.13.1. BUSINESS OVERVIEW
21.13.2. PRODUCT OFFERINGS
21.14. THE EAST AFRICA WAX COMPANY
21.14.1. BUSINESS OVERVIEW
21.14.2. PRODUCT OFFERINGS
21.15. VAV LIFE SCIENCES (VAV)
21.15.1. BUSINESS OVERVIEW
21.15.2. PRODUCT OFFERINGS
21.16. WAXOILS
21.16.1. BUSINESS OVERVIEW
21.16.2. PRODUCT OFFERINGS
22. REPORT SUMMARY
22.1. KEY TAKEAWAYS
22.2. STRATEGIC RECOMMENDATIONS
23. QUANTITATIVE SUMMARY
23.1. MARKET BY GEOGRAPHY
23.1.1. FATS
23.1.2. PHOSPHOLIPIDS
23.1.3. OILS
23.1.4. WAXES
23.1.5. OTHERS
23.1.6. SOLUBILIZERS & WETTING AGENTS
23.1.7. EMULSIFIER & SURFACTUNT
23.1.8. STRUCTURING AGENTS & LUBRICANTS
23.1.9. EMOLLIENTS, PENETRATION ENHANCERS, & SOLVENTS
23.1.10. OTHERS
23.1.11. ENTERAL
23.1.12. INJECTABLES
23.1.13. TOPICAL
23.1.14. PHARMA & BIOTECH COMPANIES
23.1.15. CMOS
23.1.16. CROS & CDMOS
23.1.17. ACDEMIC & RESEARCH INSTITUTES
23.2. MARKET BY PRODUCT TYPE
23.2.1. NORTH AMERICA
23.2.2. EUROPE
23.2.3. APAC
23.2.4. LATIN AMERICA
23.2.5. MIDDLE EAST & AFRICA
23.3. MARKET BY FUNCTIONALITY
23.3.1. NORTH AMERICA
23.3.2. EUROPE
23.3.3. APAC
23.3.4. LATIN AMERICA
23.3.5. MIDDLE EAST & AFRICA
23.4. MARKET BY FORMULATION
23.4.1. NORTH AMERICA
23.4.2. EUROPE
23.4.3. APAC
23.4.4. LATIN AMERICA
23.4.5. MIDDLE EAST & AFRICA
23.5. MARKET BY END-USER
23.5.1. NORTH AMERICA
23.5.3. EUROPE
23.5.5. APAC
23.5.7. LATIN AMERICA
23.5.9. MIDDLE EAST & AFRICA
24. APPENDIX
24.1. RESEARCH METHODOLOGY
24.2. RESEARCH PROCESS
24.3. REPORT ASSUMPTIONS & CAVEATS
24.3.1. KEY CAVEATS
24.3.2. CURRENCY CONVERSION
24.4. ABBREVIATIONS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings